Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

Inclusion Criteria:

• HIV-1 infection as documented by ELISA and confirmed by either Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA by RT-PCR or bDNA at any time prior to study entry.
• Receipt of ARV medication uninterrupted for > 1 year leading up to the screening period with demonstrated HIV RNA < 50 copies/ml for a period of 1 year."
• Willingness for both males and females of childbearing potential to utilize 2 effective contraception methods (2 separate forms, one of which must be an effective barrier method), be non-heterosexually active or have a an exclusive vasectomized partner from screening throughout the duration of the study treatment and for 30 days following the last dose of study drugs.
• Age >18 years.
• Ability and willingness to provide written informed consent

• The following laboratory parameters documented within 30 days prior to study entry:

  • Hemoglobin >8.0
  • Absolute neutrophil count >500
  • Platelet count >40,000
  • AST (SGOT) and ALT (SGPT) <5 x ULN
  • Creatinine <1.5 x ULN
  • Lipase <2.0 x ULN
  • Estimated creatinine clearance > 60 mL/min.
• HIV DNA within peripheral blood mononuclear cells > 100 copies/mL
• Not currently receiving Maraviroc as part of ARV regimen

Exclusion Criteria:

• Past or present HIV opportunistic infection of the brain, learning disability, head injury with prolonged loss of consciousness or cognitive sequelae, or other non-HIV risk factor that may impact cognitive performance.
• Any factor that precludes MRI scan including presence of metal or exposure to metal work (e.g., metal grinder/worker) and claustrophobia
• History of seizure disorder
• History of myocardial infarction, angina, congestive heart failure, peripheral vascular disease, angioplasty or cardiac surgery
• Current malignancy or history of past malignancies excluding basal cell CA
• Any immunomodulator, HIV vaccine, or investigational therapy within 30 days of study entry.
• Any vaccination within 30 days of study entry.
• Requirement for acute therapy for other AIDS-defining illness or other serious medical illnesses (in the opinion of the site investigator) within 14 days prior to study entry.
• Other chronic illnesses including diabetes, autoimmune diseases, and endocrinopathies, except subjects on stable physiologic replacement therapy for low testosterone or thyroid levels
• Known hypersensitivity to Maraviroc
• Any condition which, in the opinion of the investigator, would compromise the subject's ability to participate in the study
• Current active substance or alcohol dependence
• Pregnancy or breast-feeding, intent to become pregnant during the course of the study.